but a US appeals court in 2020 reinstated the $235 million judgment against the generics manufacturer. Fast forward to February of this year, and the US Court of Appeals declined Teva's request to ...
GlobalData on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
GlobalData on MSN1d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Swiss generic drug manufacturer Sandoz has agreed to pay $275 million to resolve claims by U.S. consumers and others who ...
1 Day TEVA 1.97% DJIA 0.02% S&P 500 0.24% Health Care/Life Sciences 0.00% ...
Teva's Growth Profile Looks Strong From Innovative Portfolio, Biosimilar Approvals and Deep Pipeline
Teva Pharmaceutical is one of the leading global ... halt production and meaningfully hurt the firm's top line as well as brand reputation. However, we don't see this as a likely scenario.
Regulatory ApprovalFormycon receives regulatory approval in the UK for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand name AHZANTIVE® 25.02.2025 / 06:30 CET/CESTThe issuer is solely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback